Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brigitte C Widemann

Showing results (111-120 of 203) with videos related to

Pageof 21
Sort By:
Journal of Neuro-Oncology|February 19, 2024
Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannomaPhioanh Leia Nghiemphu, Jeremie Vitte, Eva Dombi, et al.
Neurology|July 7, 2021
Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical TrialsAshley Cannon, Dominique C Pichard, Pamela L Wolters, et al.
Neuro-Oncology Advances|September 17, 2020
The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromasSadhana Jackson, Eva H Baker, Andrea M Gross, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2006
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromasBrigitte C Widemann, Wanda L Salzer, Robert J Arceci, et al.
The Oncologist|October 29, 2017
Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate ClearanceLaura B Ramsey, Frank M Balis, Maureen M O'Brien, et al.
Pediatric Blood & Cancer|April 26, 2018
A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology GroupMeredith K Chuk, Brigitte C Widemann, Charles G Minard, et al.
Neuro-Oncology|February 7, 2018
The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumorsChristine S Higham, Eva Dombi, Aljosja Rogiers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumorsElizabeth Fox, John M Maris, Brigitte C Widemann, et al.
The Laryngoscope|December 30, 2022
Audiometric and Otologic Findings in Children and Young Adults with Neurofibromatosis Type 1 and Plexiform NeurofibromasVictoria Idowu, Julie Christensen, Andrea M Gross, et al.
Cancer Genetics|April 9, 2021
Ataxia telangiectasia mutated germline pathogenic variant in adrenocortical carcinomaMadeline B Torres, Laurence P Diggs, Jun S Wei, et al.
Pageof 21

Showing results (111-120 of 203) with videos related to

Sort By:
Pageof 21
Journal of Neuro-Oncology|February 19, 2024
Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannomaPhioanh Leia Nghiemphu, Jeremie Vitte, Eva Dombi, et al.
Neurology|July 7, 2021
Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical TrialsAshley Cannon, Dominique C Pichard, Pamela L Wolters, et al.
Neuro-Oncology Advances|September 17, 2020
The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromasSadhana Jackson, Eva H Baker, Andrea M Gross, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2006
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromasBrigitte C Widemann, Wanda L Salzer, Robert J Arceci, et al.
The Oncologist|October 29, 2017
Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate ClearanceLaura B Ramsey, Frank M Balis, Maureen M O'Brien, et al.
Pediatric Blood & Cancer|April 26, 2018
A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology GroupMeredith K Chuk, Brigitte C Widemann, Charles G Minard, et al.
Neuro-Oncology|February 7, 2018
The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumorsChristine S Higham, Eva Dombi, Aljosja Rogiers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumorsElizabeth Fox, John M Maris, Brigitte C Widemann, et al.
The Laryngoscope|December 30, 2022
Audiometric and Otologic Findings in Children and Young Adults with Neurofibromatosis Type 1 and Plexiform NeurofibromasVictoria Idowu, Julie Christensen, Andrea M Gross, et al.
Cancer Genetics|April 9, 2021
Ataxia telangiectasia mutated germline pathogenic variant in adrenocortical carcinomaMadeline B Torres, Laurence P Diggs, Jun S Wei, et al.
Pageof 21